TSHA
Taysha Gene Therapies, Inc.
There isn't enough reported data to score TSHA yet.
TSHA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
TSHA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
TSHA PE Valuation
TSHA has no meaningful PE right now: it lost money over the past year.
TSHA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| High |
Analysts expect TSHA's losses to grow, with revenue declining.
TSHA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.43 | -$0.10 |
| Q2 2026 | -$0.42 | -$0.08 |
| Q1 2026 | -$0.38 | -$0.04 |
| Q4 2025 | -$0.34 | +$0.02 |
| Q3 2025 | -$0.33 | -197% |
| Q2 2025 | -$0.34 | +$0.15 |
| Q1 2025 | -$0.34 | +$0.44 |
| Q4 2024 | -$0.36 | +$0.60 |
TSHA is still losing money, but far less than before: $0.43 per share over the past year, against $5.08 at its worst in early 2022.
TSHA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $5.5M | +171% |
| Q2 2025 | $2M | +79% |
| Q1 2025 | $2.3M | -33% |
| Q4 2024 | $2M | -44% |
| Q3 2024 | $1.8M | -62% |
| Q2 2024 | $1.1M | -54% |
| Q1 2024 | $3.4M | -28% |
TSHA's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -516% | +470 points |
| Q2 2025 | -1347% | +568 points |
| Q1 2025 | -931% | -217 points |
| Q4 2024 | -986% | -535 points |
| Q3 2024 | -1448% | -1106 points |
| Q2 2024 | -1915% | -939 points |
| Q1 2024 | -713% | -361 points |
| Q4 2023 | -451% | N/A |
TSHA's operating margin was −516% last quarter, up 932 points from the same quarter a year ago.
TSHA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$33.4M | -$9.1M |
| Q1 2026 | -$40.9M | -$18.9M |
| Q4 2025 | -$27M | -$8.7M |
| Q3 2025 | -$24.3M | -$2.6M |
| Q1 2025 | -$22M | -$2.1M |
| Q4 2024 | -$18.3M | -$2.2M |
| Q3 2024 | -$21.7M | -$3.7M |
| Q2 2024 | -$21.7M | -$3M |
TSHA has burned cash in almost every quarter: −$142M over the past year, against −$86M the year before.
TSHA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +37.1M shares |
| 1 year | +15% | +52.8M shares |
| 3 years | +532% | +342M shares |
| 5 years | +998% | +369M shares |
| Available history | +2577% | +391M shares |
TSHA has 406M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
TSHA Net Leverage
TSHA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TSHA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 23.3 | Neutral |
TSHA's weekly RSI is 41 (neutral) and its Stochastic is 23 (neutral).
TSHA PE vs Healthcare Sector
| Metric | TSHA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TSHA has no meaningful PE right now: it lost money over the past year.
TSHA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.25 | 0.9% below |
| 20 week MA | $5.21 | 19% below |
| 50 week MA | $5.25 | 20% below |
| 100 week MA | $3.94 | 6.9% above |
| 200 week MA | $2.92 | 44% above |
TSHA has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 44% above its 200-week average.
TSHA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.5 | $27.2 | +11% |
| 2021 | $27.2 | $12.8 | -53% |
| 2022 | $12.8 | $2.08 | -84% |
| 2023 | $2.08 | $1.77 | -15% |
| 2024 | $1.77 | $1.75 | -1.1% |
| 2025 | $1.75 | $5.83 | +233% |
| 2026 YTD | $5.83 | $4.21 | -28% |
TSHA's yearly returns have swung widely, from +233% in 2025 to −84% in 2022. It's down 28% so far in 2026.